Key clinical point: A group of hemophilia experts provided recommendations on immune tolerance induction in patients with hemophilia A with inhibitors.
Major finding: The concurrent use of factor VIII replacement therapy and emicizumab could inhibit bleeding with lower dose immunotolerance treatment strategies.
Study details: Consensus recommendations provided by a nine-member expert committee.
Disclosures: The manuscript was supported by Grifols. The authors reported financial affiliations with Bayer, Bioverativ, CSL Behring, Grifols, Kedrion, Novo Nordisk, Pfizer, and several others.
Carcao M et al. Haemophilia. 2019 Apr 29. doi: 10.1111/hae.13762